Cramer's Mad Dash: Moderna gets upgrade from HSBC
CNBC's Jim Cramer reports on the latest news regarding Moderna. 'Mad Money' host Jim Cramer looks at the recent move down in ...
The Score: Spirit, Tesla, Moderna and More Stocks That Defined the Week
Big pharma stocks needed a shot in the arm after Donald Trump chose vaccine skeptic Robert F. Kennedy Jr. as health secretary ...
Seeking Alpha on MSN54m
BioNTech started at buy, Moderna at hold by Berenberg
Berenberg has initiated coverage of BioNTech (NASDAQ:BNTX) and Moderna (NASDAQ:MRNA), citing their leadership positions in mRNA medicine. The investment firm started BioNTech (BNTX) with a buy rating ...
Moderna initiated with a Hold at Berenberg
Berenberg analyst Harry Gillis initiated coverage of Moderna (MRNA) with a Hold rating and $42 price target. The firm says mRNA will ...
Moderna’s Strategic Shift and Financial Outlook Leads to Sell Rating and Lowered Price Target
Leerink Partners analyst Mani Foroohar has reiterated their bearish stance on MRNA stock, giving a Sell rating on November 14.Don't Miss our ...
Moderna, with aid of TBWA\Chiat\Day, is making mRNA science exciting & accessible
With the help of TBWA\Chiat\Day New York, pharma giant Moderna is demystifying mRNA science for the average consumer. This ...
Moderna stock climbs as HSBC upgrades to Buy on underestimated pipeline potential
Shares in biotech firm Moderna (NASDAQ: MRNA) rose more than 4% Monday after HSBC raised its rating on the stock from Hold to ...
The Art Newspaper24m
From neon installations to an animatronic bear, here's what not to miss this Turin Art week
Turin Art week may be focused around Artissima, Italy’s oldest art fair, but there's must-see exhibitions to found across the ...
Moderna, Lily, Novavax, and Pfizer stocks fall after Trump nominates RFK Jr. as health secretary
Drug manufacturers saw their stock prices fall on Friday after vaccine skeptic Robert F. Kennedy Jr. was announced as Trump's ...
Moderna Remains Confident Despite Political Concerns Over Vaccine Safety and HHS Nomination
Moderna plans to prioritize new product approvals and oncology investments, as political concerns over Robert F. Kennedy Jr.'s HHS nomination weigh on vaccine stocks.
Moderna's stock decline after RFK Jr's appointment makes an "attractive entry point": Piper Sandler
Moderna’s ( NASDAQ: MRNA) steep fall on Friday after President-elect Donald Trump selected vaccine critic Robert F. Kennedy Jr. to head the U.S. Department of Health and Human Services makes a good ...
Moderna, Pfizer Stocks Fall After Reports of RFK Jr. Nomination
Shares of vaccine-makers fell after reports that Donald Trump is expected to nominate vaccine skeptic Robert F. Kennedy Jr.